Abstract
Most of relevant strategies designed for therapeutic targeting the highly lethal, bone-metastasizing and AR-resistant prostate cancers, have been reported and discussed elsewhere in this book. In this chapter, we aim to provide an overview of the rationale underlying the proposal of most of promising new therapeutic alternatives, most of which are still the early phase of evaluation.
Once more, we strongly wish to outline that the deeper understanding of the intricate crosstalks between the manifold molecular pathways responsible for the gain of invasive and metastasizing abilities of tumor cells, is giving rise to a previously unthinkable picture of the complex prostate cancer biology. A new, fascinating therapeutic era is opening up for the treatment of advanced prostate cancers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M, Ballatore Z, Savini A, De Lisa M, Caramanti M, Rinaldi S, Pagliaretta S, Santoni M, Pierantoni C, Cascinu S (2013) Role of maspin in cancer. Clin Transl Med 2(1):8. doi:10.1186/2001-1326-2-8
Bijnsdorp IV, Rozendaal L, van Moorselaar RJ, Geldof AA (2012) A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis. Br J Cancer 107(12):1963–1968
Brennen WN, Chen S, Denmeade SR, Isaacs JT (2013) Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget 4(1):106–117
Bussard KM, Gay CV, Mastro AM (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27(1):41–55, Review
Carlsson J, Shen L, Xiang J, Xu J, Wei Q (2013) Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncol Lett 5(1):208–214
Fang YX, Gao WQ (2013) Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. doi: 10.1038/onc.2013.54. Epub ahead of print
Fenderico N, Casamichele A, Profumo V, Zaffaroni N, Gandellini P (2013) MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets. Curr Med Chem 20(12):1566–1584
Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES (2012) PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res 10(12):1555–1566
Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev 25(4):521–529, Review
Mimeault M, Batra SK (2013) Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17(1):30–54, Epub 2013 Jan 10
Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O (2013) The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers. PLoS One 8(1):e54251, Epub 2013 Jan 16
Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68(18):3033–3046, Epub 2011 Jun 3
Schroten C, Dits NF, Steyerberg EW, Kranse R, van Leenders AG, Bangma CH, Kraaij R (2012) The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression. Cancer Immunol Immunother 61(6):905–910
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810):39–46
Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ (2011) Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 71(6):615–625
Xiong SW, Lin TX, Xu KW, Dong W, Ling XH, Jiang FN, Chen G, Zhong WD, Huang J, Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, Chen Z, Chen Z, Shin DM, Yuan H (2013) MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res 19(3):529–537, Epub 2013 Mar 3
Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK (2012) Evidence of mTOR activation by an AKT-independent mechanism provides support for the combined treatment of PTEN-deficient prostate tumors with mTOR and AKT inhibitors. Transl Oncol 5(6):422–429
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Simeone, E. et al. (2013). Therapeutic Targeting of the Bone Pre-metastatic Niche. In: Staibano, S. (eds) Prostate Cancer: Shifting from Morphology to Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7149-9_16
Download citation
DOI: https://doi.org/10.1007/978-94-007-7149-9_16
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7148-2
Online ISBN: 978-94-007-7149-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)